- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01690897
Randomized Comparison of Mindfulness Versus Group Support for Treatment of Low Sexual Desire in Women (DESIRE)
November 5, 2024 updated by: Lori Brotto, University of British Columbia
The purpose of this study is to determine whether an 8-session mindfulness-based intervention (MBCT group) is effective for women with low sexual interest/desire in reducing sexual distress, improving their sexual response, and increasing their mindful skills, compared to a support group.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
HYPOTHESES:
- Compared to baseline, the MBCT group will have significant post-treatment improvements in self-report measures of: (a) sexual distress; (b) sexual desire, subjective sexual arousal, perception of genital arousal, and sexual pleasure; (c) relationship satisfaction; (d) depressive symptoms and rumination; (e) perceived stress, general anxiety, anxiety sensitivity, and sexuality-related situational anxiety (as self-reported at the sexual arousal assessment); and (f) mindfulness, self-compassion, non-attachment, and interoceptive awareness.
- Compared to baseline, the MBCT group will have significant post-treatment improvements in laboratory physiological measures of: (a) genital sexual response as measured by a vaginal photoplethysmograph, (b) interoceptive awareness, as measured by a heart rate perception task, and (c) cortisol:DHEA ratio as measured by hormonal assays of saliva samples.
- We hypothesize that the changes in the endpoints listed in #1 or #2 will be significantly greater in the MBCT group than in the support group.
- We hypothesize that participation in the MBCT group will significantly increase concordance between genital and subjective sexual arousal.
- Mindfulness, self-compassion, and interoceptive awareness will significantly mediate improvements in sexual distress and desire in the MBCT group at all post-treatment assessment points.
- Expectations of change with treatment will not significantly moderate improvements in sexual distress and desire in the MBCT group.
- Participants' impressions of change will be significantly greater in the MBCT group compared to the support group at all post-treatment assessment points.
- We hypothesize that participants will experience fewer breaks in the sexual response cycle throughout the course of the eight-week treatment.
Study Type
Interventional
Enrollment (Actual)
149
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Department of Gynaecology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- must be experiencing distressing sexual interest/desire and/or sexual arousal concerns
- must between the ages of 19 - 65
- must be fluent in English
Exclusion Criteria:
- not experiencing distressing sexual interest/desire and/or sexual arousal concerns
- not between the ages of 19-65
- unable to read, write, speak and understand English
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: MBCT group
Women randomized into the MBCT group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the mindfulness-based treatment.
|
The mindfulness-based treatment for the MBCT group treatment consists of eight 2-hour long weekly sessions, based on a variety of empirically supported techniques, and integrates elements of education, mindfulness skills, and sex therapy.
In addition, participants are also given handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and behavioural exercises between sessions.
|
|
Active Comparator: Support group
Women randomized into the support group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the sex therapy, education, and support treatment.
|
The sex therapy, education, and support group will consist of all of the same techniques and materials in the MBCT group except for the mindfulness components in group sessions and at-home practices.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Female Sexual Distress Scale-Revised (FSDS-R)
Time Frame: 2-4 weeks post treatment (10-12 weeks after start of treatment), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start of treatment). Assessments completed past 1 year were due to personal delays by co-investigator.
|
Sexual distress will be measured with the revised version of the Female Sexual Distress Scale-R (Derogatis et al., 2008).
Scores on the scale range from 0 - 48, where higher scores represent higher levels of distress.
|
2-4 weeks post treatment (10-12 weeks after start of treatment), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start of treatment). Assessments completed past 1 year were due to personal delays by co-investigator.
|
|
Sexual Interest and Desire Inventory (SIDI)
Time Frame: 2-4 weeks post treatment (10-12 weeks after start of treatment), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start of treatment). Assessments completed past 1 year were due to personal delays by co-investigator.
|
The Sexual Interest and Desire Inventory (SIDI; Clayton et al. 2006) will be used to measure sexual desire.
Possible total scores range from 0 - 51, with higher scores indicating higher levels of sexual functioning.
|
2-4 weeks post treatment (10-12 weeks after start of treatment), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start of treatment). Assessments completed past 1 year were due to personal delays by co-investigator.
|
|
Rumination
Time Frame: 2-4 weeks post treatment (10-12 weeks after start of treatment), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start of treatment). Assessments completed past 1 year were due to personal delays by co-investigator.
|
Rumination was measured with the Rumination-Reflection Questionnaire - Adapted Rumination Subscale (adapted from Trapnell & Campbell, 1999 to inquire about sexuality-related rumination).
Likert scale 1 - 5 with higher score indicating higher rumination.
|
2-4 weeks post treatment (10-12 weeks after start of treatment), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start of treatment). Assessments completed past 1 year were due to personal delays by co-investigator.
|
|
Relationship Assessment Scale (RAS)
Time Frame: 2-4 weeks post treatment (10-12 weeks after start of treatment), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start of treatment). Assessments completed past 1 year were due to personal delays by co-investigator.
|
Relationship satisfaction will be measured with the Relationship Assessment Scale (Hendrick, 1988).
Scoring: Add each item score and divide by 7 to get a mean score.
Higher score relates to higher satisfaction.
Minimum mean score 1, maximum score 5.
|
2-4 weeks post treatment (10-12 weeks after start of treatment), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start of treatment). Assessments completed past 1 year were due to personal delays by co-investigator.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subjective Sexual Arousal
Time Frame: Up to 2 mos pre-treatment, 2-4 weeks post treatment (10-12 weeks after treatment start), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start). Assessments completed past 1 year were due to personal delays by Co-I
|
Subjects will indicate their levels of subjective arousal while undergoing arousal testing.
A device manufactured for the UBC Sexual Health Lab called the "arousometer"- a computer mouse mounted on a metal track divided into 10 equally spaced intervals corresponding to "sexually turned off" (-2) to "the most sexually aroused you have ever been or could imagine being" (7).
This device allows continuous self-report measurement of subjective sexual arousal while viewing the erotic films.
|
Up to 2 mos pre-treatment, 2-4 weeks post treatment (10-12 weeks after treatment start), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start). Assessments completed past 1 year were due to personal delays by Co-I
|
|
Interoceptive Awareness
Time Frame: Up to 2 mos pre-treatment, 2-4 weeks post treatment (10-12 weeks after treatment start), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start). Assessments completed past 1 year were due to personal delays by Co-I
|
Interoceptive awareness will be measured using the Multidimensional Assessment of Interoceptive Awareness (MAIA; Mehling et al., 2012) questionnaire.
Possible range of scores 0 - 5. Higher score means higher awareness.
|
Up to 2 mos pre-treatment, 2-4 weeks post treatment (10-12 weeks after treatment start), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start). Assessments completed past 1 year were due to personal delays by Co-I
|
|
Physiological Sexual Arousal
Time Frame: Up to 2 mos pre-treatment, 2-4 weeks post treatment (10-12 weeks after treatment start), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start). Assessments completed past 1 year were due to personal delays by Co-I
|
Physiological sexual arousal will be measured with a Vaginal Photoplethysmograph (VPP) during exposure to erotic films.
The VPP measures vaginal pulse amplitude (VPA) which has been found to be a sensitive and specific measure of genital arousal (Laan & Everaerd, 1995).
There is no threashold on the millivolts (MV) reading.
|
Up to 2 mos pre-treatment, 2-4 weeks post treatment (10-12 weeks after treatment start), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start). Assessments completed past 1 year were due to personal delays by Co-I
|
|
Stress Hormone Cortisol Slope
Time Frame: Up to 2 mos pre-treatment, 2-4 weeks post treatment (10-12 weeks after treatment start), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start). Assessments completed past 1 year were due to personal delays by Co-I
|
The diurnal cortisol slope is the difference in cortisol levels from morning to evening (PM minus AM).
To assay salivary cortisol concentrations, samples were vortexed and centrifuged at 1,400 g for 10 minutes at 18°C.
Salivary cortisol was measured using the commercially available High Sensitivity Salivary Cortisol Enzyme Immunoassay Kit (Salimetrics Assays, 1-3002, State College, PA) according to the standard protocol.
The minimum amount of saliva required by this assay is 25 μl, and intra- and inter-assay coefficients of variation were 4.6% and 6.0%, respectively.
|
Up to 2 mos pre-treatment, 2-4 weeks post treatment (10-12 weeks after treatment start), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start). Assessments completed past 1 year were due to personal delays by Co-I
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Depression
Time Frame: Up to 2 mos pre-treatment, 2-4 weeks post treatment (10-12 weeks after treatment start), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start). Assessments completed past 1 year were due to personal delays by Co-I
|
Depression is measured with the Hamilton Depression Scale - Short Form (McIntyre et al., 2005).
Seven questions on a scale of 0 - 4 with higher score meaning higher depression.
Totals are summed with a possible range of scores from 0 - 28.
|
Up to 2 mos pre-treatment, 2-4 weeks post treatment (10-12 weeks after treatment start), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start). Assessments completed past 1 year were due to personal delays by Co-I
|
|
Mindfulness
Time Frame: Up to 2 mos pre-treatment, 2-4 weeks post treatment (10-12 weeks after treatment start), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start). Assessments completed past 1 year were due to personal delays by Co-I
|
Mindfulness will be measured with the Five Factor Mindfulness questionnaire (Baer, Smith, Hopkins, Krietemeyer & Tony, 2006).
Questions are answered on a 5-point Likert scale ranging from 1 to 5. Possible range of scores 39 to 195 with higher score meaning higher mindfulness.
|
Up to 2 mos pre-treatment, 2-4 weeks post treatment (10-12 weeks after treatment start), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start). Assessments completed past 1 year were due to personal delays by Co-I
|
|
Perceived Stress
Time Frame: Up to 2 mos pre-treatment, 2-4 weeks post treatment (10-12 weeks after treatment start), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start). Assessments completed past 1 year were due to personal delays by Co-I
|
Perceived stress will be measured with the Perceived Stress Scale (Cohen, Kamarck, & Mermelstein, 1983).
Questions are likert scale from 0 - 4. Possible range of scores 0 - 40 with higher score indicating higher stress.
|
Up to 2 mos pre-treatment, 2-4 weeks post treatment (10-12 weeks after treatment start), 6 months post (approx 8 months after start), and 12 months post (approx 14 months after start). Assessments completed past 1 year were due to personal delays by Co-I
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lori A Brotto, PhD, University of British Columbia
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2015
Primary Completion (Actual)
December 31, 2019
Study Completion (Actual)
March 1, 2020
Study Registration Dates
First Submitted
August 22, 2012
First Submitted That Met QC Criteria
September 21, 2012
First Posted (Estimated)
September 24, 2012
Study Record Updates
Last Update Posted (Actual)
December 13, 2024
Last Update Submitted That Met QC Criteria
November 5, 2024
Last Verified
November 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- H12-01659
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low Female Sexual Desire
-
University of British ColumbiaCompletedLow Female Sexual Arousal | Low Female Sexual DesireCanada
-
Bio Nature HealthCitruslabsCompletedLow Libido | Sexual; Desire AbsentUnited States
-
TriHealth Inc.TriHealth Medical Education Research FundCompletedHypoactive Sexual Desire Disorder (HSDD) | Low Libido | Female Sexual Dysfunction (FSD)United States
-
Ivix LLXCompletedFemale Sexual Dysfunction | Hypoactive Sexual Desire Disorder | Sexual Desire DisorderRussian Federation
-
University of British ColumbiaRecruiting
-
Dame Products, Inc.CitruslabsCompletedSexual Desire DisorderUnited States
-
Ivix LLXCompletedHypoactive Sexual Desire Disorder(HSDD)Russian Federation
-
Ivix LLXCompletedHypoactive Sexual Desire Disorder (HSDD)Russian Federation
-
Federal University of Minas GeraisCompletedHypoactive Sexual Desire DisfunctionBrazil
-
Bezmialem Vakif UniversityUnknownMenopause | Hypoactive Sexual Desire Disorder | Sexual Desire DisorderTurkey
Clinical Trials on Mindfulness-based treatment
-
Lund UniversityCompleted
-
Ruhr University of BochumUniversity of British Columbia; Friedrich-Alexander-Universität Erlangen-NürnbergCompletedHypoactive Sexual Desire DisorderGermany
-
University of AarhusAarhus University Hospital; TrygFonden, Denmark; Copenhagen University Hospital... and other collaboratorsCompleted
-
University Hospital TuebingenUnknownDepressive Disorder | Depression | RuminationGermany
-
University of FloridaNational Institute on Aging (NIA)CompletedCognitive AgingUnited States
-
Uniformed Services University of the Health SciencesCompleted
-
NYU Langone HealthCompleted
-
Leiden University Medical CenterZonMw: The Netherlands Organisation for Health Research and Development; University...Unknown
-
Kovacs FoundationFondo de Investigacion Sanitaria; Universitat Autonoma de Barcelona; Spanish...Completed
-
Canterbury Christ Church UniversityUniversity of SurreyCompletedThe Quality of Life of Parents of Children With Food AllergyUnited Kingdom